Product
Supplier
Encyclopedia
Inquiry
Home > Pharmaceutical Intermediates > Bulk Drug Intermediates > Tirzepatide for Sale > Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings
Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings buy - large image1
Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings buy - image1
Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings buy - image2
Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings buy - image3
Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings buy - image4
Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings buy - image5
Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings buy - image6

Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings

TDS 2099 Inquiries

Unit Price: Get Latest Price
CAS No.:

2023788-19-2

Grade:

Top Product

Content:

99%

Port:

shanghai

Brand:

COMINGS

Packaging:

1g,50g,100g,1000g

Price valid (until):

2025-06-26

Company Type:
Trader
Location:
China
Payment Terms:
TT against copy of documents,100% TT in advance
Average Lead Time:
15 days
Qualification:
Main Products:

semaglutide,tirzepatide,Liraglutide,Retatrutide,5-amino-1MQ,SLU-PP-332

  • Product Details

  • Seller Information

  • Inquiry History

  • Description
    Items Specifications
    CAS:  2023788-19-2
    Name: Tirzepatide raws
    Synonyms Name: LY3298176
    Molecular formula:  C225H348N48O68
    Molecular Weight:  3751.20000
    Color white


      Product Detail  


    • The Usage Of Tirzepatide Raw Powder


      Tirzepatide is an innovative drug that is the first and currently only glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Discovery of this drug brings new hope for treatment of diabetes patients


      What Is Tirzepatide?


      Tirzepatide is a newer medication that belongs to the class of drugs called dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. It's being investigated for its potential use in managing type 2 diabetes and obesity.

      This medication works by activating both the GIP and GLP-1 receptors, which play important roles in glucose metabolism and appetite regulation. By stimulating these receptors, tirzepatide can help regulate blood sugar levels by increasing insulin secretion and decreasing glucagon production, leading to better control of blood glucose.
      In addition to its effects on blood sugar, tirzepatide has shown promising results in clinical trials for promoting weight loss. Its dual action on appetite regulation makes it a potential option for managing obesity.
      Tirzepatide is typically administered via subcutaneous injection and is still undergoing clinical trials to determine its safety, efficacy, optimal dosage, and long-term effects. As with any medication, it's important to consider potential side effects and discuss its use with a healthcare professional.
      The development of tirzepatide represents a novel approach in diabetes and obesity management. Further studies and regulatory approvals are necessary to establish its role in the treatment landscape for these conditions.


    • The Packaging Of Liraglutide

      1g,50g,100g,1000g

    Wuhan Comings Biotechnology Co., Ltd. was established in 2016. Since its establishment, the company has always been committed to making more people healthy, making more people young and happy, and providing customers with high-quality and efficient services.

    The company cooperates with biological experts from many universities, adopts modern gene cloning technology and unique purification technology, and strictly controls all aspects. The adipotide we produce are sold well in Europe, Africa, and America, and many customers have given good reviews.

    And our company has storage bases in Shenzhen, Shanghai, Qingdao ports to ensure that all goods can arrive safely, on time and quickly.

    Wuhan Comings Biotechnology Co., Ltd. is looking forward to cooperating with you with professional knowledge, high-quality service and competitive price!

    Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 1

    Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 2Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 3Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 4Shop JBSNF-000088/-Methoxynicotinamide 98% Powder 7150-23-4 COMINGS-Detailed Image 5

    Shop Weight Loss GLP-1 Injection Peptide 99% Purity Tirzepatide(LY3298176) Semaglutide/COMINGS-Detailed Image 6

    ECHEMI Editorial Reference

    Tirzepatide (LY3298176) was developed as a dual agonist to both GLP-1 and gastric inhibitory polypeptide (GIP) receptors (Frias et al., 2018). Similar to GLP-1, GIP is an incretin hormone that functions to induce insulin secretion.

    Certificates
    • Weight Loss GLP-1 Injection Peptide 99% Purity glp1 agonist Tirzepatide Comings Certificates 1 TDS

    Basic Info
    Product Name:

    Tirzepatide

    Other Name:

    LY3298176;

    CAS No.:

    2023788-19-2

    Molecular Formula:

    C225H348N48O68

    Molecular Weight:

    4813

    EC Number:

    200-001-8

    Characteristics
    Appearance:

    White to off-white

    Research
    Class:

    Dual agonist — GIPR, GLP-1R

    Status:

    FDA-approved (Mounjaro / Zepbound)

    Mechanism:

    Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. A 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding for extended half-life (~5 days). Selectively activates both GIPR and GLP-1R signaling pathways.

    EC50 (Human GLP1R):

    0.934 nM

    EC50 (Human GIPR):

    0.0224 nM

    Source:

    Frias JP, et al. N Engl J Med. 2021;385(6):503-515.DOI

    FDA:

    Mounjaro, Zepbound (approved 2022-05-13)

    References
    ChEMBL:

    CHEMBL4297839

    DrugBank:

    DB15171

    KEGG DRUG:

    D11360

    PubChem:

    PubChem

    Disclaimer:

    Tirzepatide is approved as a prescription medicine (Mounjaro, Zepbound) in certain jurisdictions. This listing is for industrial and laboratory research use only. Research-chemical listings on B2B marketplaces are not interchangeable with approved medicines. Confirm CAS, specification, and regulatory pathway with the seller. It is not medical advice, a clinical recommendation, or an approved therapy description.

  • Seller Information
    Business Type:

    Trader

    Main Products:

    semaglutide,tirzepatide,Liraglutide,Retatrutide,5-amino-1MQ,SLU-PP-332

    Location:

    No. 1, 19th Floor, Unit 2, Building 5, Southeast Residential Building (Hankou Yujiang Lanting), at the intersection of Hanshi Highway and Fufa South Road, Wuhu Street, Huangpi District, Wuhan City, Hu

    Payment Terms:

    TT against copy of documents,100% TT in advance

    Average lead Time:

    15 days

    Total Annual Revenue:

    $1 million-$2.5 million

    Total Employees:

    11-50

    Year of Establishment:

    2023

    We prospectively allocates international cutting-edge production and testing equipment and environmental protection facilities. The 5 production lines can achieve an annual output of 1000Kg. We to be the best chemical manufacture in China,and will become a trustworthy supplier of chemicals for global customers.
    Our main products include peptides, cognitive enhancers, pharmaceutical intermediates, and botanical extracts.
    And our main clients cover: pharmaceutical companies, hospitals, laboratories in higher education institutions, and cosmetic companies.
    Since its establishment, our company's products have been exported to regions including Europe, the Americas, the Middle East and so on. Our commitment to high product quality and excellent after-sales service has provided customers with a positive experience.
    Wuhan Comings Biotechnology Co., Ltd. is looking forward to cooperating with you with professional knowledge, high-quality service and competitive price!
  • Inquiry History
    2099 Inquiries
    Country Product Purchase Quantity Date Posted
    Philippines

    Tirzepatide

    2 MT Oct 27, 2026
    Philippines

    Tirzepatide

    30 MG Oct 26, 2026
    Slovakia

    Tirzepatide

    1 G Oct 26, 2026
    France

    Tirzepatide

    1 KG Oct 25, 2026
    United States

    Tirzepatide

    2.5 MG Oct 25, 2026
    United Kingdom

    Tirzepatide

    5 MT Oct 25, 2026
    United Kingdom

    Tirzepatide

    6 MT Oct 24, 2026
    Peru

    tirzepatide

    10 MG Oct 21, 2026
    Puerto Rico

    tirzepatide

    40 MG Oct 21, 2026
    United States

    Tirzepatide

    10 MT Oct 21, 2026
    South Africa

    Tirzepatide

    1 MT Oct 20, 2026
    United States

    Tirzepatide

    5 KG Oct 20, 2026
    United States

    tirzepatide

    30 MG Oct 20, 2026
    United States

    Tirzepatide

    50 MG Oct 20, 2026
    Spain

    tirzepatide

    20 MG Oct 19, 2026
    United States

    tirzepatide

    30 MG Oct 19, 2026
    Philippines

    tirzepatide

    40 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    tirzepatide

    50 MG Oct 19, 2026
    United States

    Tirzepatide

    20 MG Oct 19, 2026
    Post an enquiry for this product
pic ×

Scan the QR Code to Share

All products displayed on this website are only for non-medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.

According to relevant laws and regulations and the regulations of this website, units or individuals who purchase hazardous materials should obtain valid qualifications and qualification conditions.

The information shown above is provided by the enterprise itself, and the authenticity, accuracy and legitimacy of the content are the responsibility of the publishing company. ECHEMI does not bear any guarantee responsibility for this. Please be aware that risks in internet transactions objectively exist.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.